Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTP-Hib vaccine (AIM Vaccine Co.)
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTP-Hib is a combination vaccine candidate developed by AIM Vaccine Co. designed to protect against four major pediatric infectious diseases: diphtheria, tetanus, pertussis (whooping cough), and Haemophilus influenzae type b (Hib) infections. The vaccine formulation integrates diphtheria toxoid, tetanus toxoid, pertussis vaccine components, and a Haemophilus influenzae type b conjugate vaccine into a single injection. Its mechanism of action involves inducing active immunity by stimulating the production of protective antibodies and potentially cellular immune responses against the toxins and surface antigens of the targeted pathogens. Currently in the preclinical research stage, this vaccine is part of AIM Vaccine's bacterial vaccine platform and aims to simplify immunization schedules by reducing the number of required injections for infants and children.
- Other names
- Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b combination vaccineDTP-Hib combination vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on DTP-Hib vaccine (AIM Vaccine Co.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTP-Hib vaccine (AIM Vaccine Co.).